Lyell Immunopharma Inc.

NASDAQ: LYEL · Real-Time Price · USD
10.62
-0.14 (-1.30%)
At close: Aug 15, 2025, 3:59 PM
10.58
-0.38%
After-hours: Aug 15, 2025, 04:10 PM EDT

Lyell Immunopharma Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Net Income
-42.68M -52.2M -191.94M -44.58M -45.81M -60.67M -52.93M -50.85M -63.89M -66.96M -8.4M -70.25M -36.32M -68.14M -83.71M -48.88M -62.59M -55.04M
Depreciation & Amortization
3.13M 3.44M 5.03M 4.68M 4.9M 5.02M 5.06M 5.1M 5.06M 5.03M 5.04M 4.62M 4.17M 4.19M 4.57M 4.09M 3.01M 1.96M
Stock-Based Compensation
5M 6.02M 8.08M 7.62M 8.28M 9.15M 8.46M 10.52M 14.22M 13.88M 18.36M 19.12M 22.41M 22.03M 21.18M 13.04M 15.25M 12.73M
Other Working Capital
n/a -7.9M 2.07M 1.6M -437K -3.12M 1.3M 3.84M 3.2M -6.38M -42.87M 1.73M -35.74M -5.33M 3.52M 6.73M -911K -5.41M
Other Non-Cash Items
87K -2.45M 131.55M -3.8M 14.09M 27.02M 15.21M -3.23M 582K 6.15M -105.78M 7.66M 3.15M -3.53M -16.2M -619K 9.96M 11.49M
Deferred Income Tax
n/a n/a n/a n/a n/a n/a -18.15M -1.65M 1.28M n/a 93.9M n/a n/a n/a 37.38M 1.09M 996K 43K
Change in Working Capital
n/a -9.55M 34K 1.04M -954K -3.24M 1.72M 2.43M 3.58M -4.31M -43.39M 1.75M -37.98M -2.39M 3.62M 5.74M -565K -4.78M
Operating Cash Flow
-34.46M -54.74M -47.24M -35.04M -38.09M -42.02M -40.63M -37.69M -39.16M -46.21M -40.27M -37.1M -44.33M -47.85M -33.17M -25.53M -33.95M -33.6M
Capital Expenditures
-168K -246K -44K -59K -331K -30K -25K -195K -933K -1.53M -4.58M -2.79M -7.17M -9.73M -10.27M -11.6M -24.45M -19.19M
Cash Acquisitions
n/a n/a -31.35M n/a n/a n/a 100.67M 78.28M 33.26M -33.69M n/a 160.79M n/a 96.2M -40K n/a 40K n/a
Purchase of Investments
-80.7M -84.41M -38.8M -131.43M -116.46M -108.01M -256.79M -78.28M -33.26M -108.56M -220.46M -160.79M -89.66M -96.2M -673.47M -275.31M -215.94M -48.29M
Sales Maturities Of Investments
93.52M 154.12M 123.7M 133.41M 161.8M 130.03M 156.12M 178.15M 187.1M 142.25M 110.9M 106.5M 121.85M 79.81M 70.33M 142.04M 200.87M 204.16M
Other Investing Acitivies
n/a n/a n/a n/a 45.34M 22.02M -100.67M -78.28M -33.26M 33.69M 160.79M -160.79M 32.19M -96.2M 539.5M -275.31M -215.9M -48.29M
Investing Cash Flow
12.65M 69.47M 53.51M 1.92M 45.01M 21.99M -100.69M 99.67M 152.91M 32.15M 46.65M -57.09M 25.02M -26.12M -73.9M -144.87M -39.47M 136.68M
Debt Repayment
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a 36.01M -734K 810K -76K -123K -215K -50K -69K -94K -367K n/a n/a n/a -531K n/a n/a
Dividend Paid
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Financial Acitivies
183K 1K n/a n/a 862K 27K 759K -143K 1.2M -69K 863K 4.76M 2.46M 2.56M 7.4M 529K 630K 884K
Financial Cash Flow
183K 1K 437K n/a 862K 27K 759K -143K 1.2M -69K 863K 4.76M 2.46M 2.56M 7.4M -531K 393.49M 884K
Net Cash Flow
-21.63M 14.73M 6.7M -33.12M 7.77M -20M -140.57M 61.84M 114.95M -14.13M 7.24M -89.43M -16.86M -71.42M -99.68M -170.94M 320.07M 103.96M
Free Cash Flow
-34.63M -54.98M -47.29M -35.1M -38.42M -42.05M -40.66M -37.88M -40.09M -47.74M -44.85M -39.89M -51.5M -57.59M -43.44M -37.13M -58.39M -52.79M